EZH2 and B-cell non-Hodgkin lymphoma: Also, CPI-1205, an orally available selective inhibitor of EZH2, killed cells in both EZH2-WT and EZH2-mutant B-cell non-Hodgkin's lymphoma by altering PRC2 target gene expression in a dose- and time-dependent manner (5).